
Pharmacally
Hidradenitis Suppurativa
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Hidradenitis Suppurativa
Clinical TrialsAbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis SuppurativaAbbVie’s Phase 3 INTREPID trial met its primary endpoint for investigational lutikizumab in moderate-to-severe hidradenitis suppurativa.Fact-Checked
Clinical TrialsTulisokibart Meets Phase 2b Endpoint in Hidradenitis SuppurativaMerck’s investigational anti-TL1A antibody tulisokibart met the primary endpoint in a Phase 2b hidradenitis suppurativa study, with HiSCR50 responses of up to 72% at week 16.Fact-Checked
Clinical TrialsMoonLake Reports Strong One-Year Phase 3 Results for Sonelokimab in Hidradenitis SuppurativaMoonLake Immunotherapeutics reported durable one-year Phase 3 data for sonelokimab in moderate-to-severe hidradenitis suppurativa, showing 67.2% HiSCR75 response rates, meaningful quality-of-life improvements, and no new safety signals.Fact-Checked
Health TidingsMoonLake Aligns with FDA on BLA Strategy for SLK in Hidradenitis SuppurativaMoonLake Immunotherapeutics said the FDA supported key elements of its planned BLA submission for sonelokimab in hidradenitis suppurativa, including efficacy analyses, adolescent patient inclusion, and safety data strategy.…Fact-Checked
Health TidingsAvalo Reports Positive Phase 2 Results for Abdakibart in HSThe Phase 2 LOTUS trial met its primary endpoint, with abdakibart demonstrating statistically significant HiSCR75 improvements and favorable safety findings in adults with moderate to severe hidradenitis suppurativa.Fact-Checked
Health TidingsBIMZELX Shows Durable Remission in Psoriasis and Sustained 3-Year Control in Hidradenitis Suppurativa at AAD 2026New BIMZELX data presented at AAD 2026 highlight high rates of sustained skin clearance in psoriasis and long-term flare control in hidradenitis suppurativa, reinforcing its durability across indications.Fact-Checked
Clinical TrialsIncyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis SuppurativaPovorcitinib showed sustained clinical responses and improved quality of life through 54 weeks in Phase 3 Hidradenitis Suppurativa trials, with regulatory reviews ongoing in the U.S. and Europe.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.